Ocugen, Inc. (OCGN) fundamentals score
Ocugen has completed enrollment in the Phase 3 liMeliGhT clinical trial for OCU400. Positive long-term, 3-year Phase 1/2 durable, safety and tolerability data for OCU400 demonstrate sustained clinically meaningful, approximately 2-line luminance visual acuity ("LLVA") gain, reinforcing durable gene-agnostic benefits.
Biological Products, (No Diagnostic Substances) · Healthcare · Listed on NASDAQ
Overall: 3.8 out of 10, Weak long-term fundamentals
- Growth: 5.4/10
- Profitability: 1.0/10
- Financial health: 3.3/10
- Earnings quality: 7.0/10
- Valuation: 3.1/10
Scores are calculated from Ocugen, Inc.’s SEC filings, using the 12 months through 2026-06. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10